Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model

Abstract

Recent studies have demonstrated the immunomodulatory effects of heat-killed lactic acid bacteria. The aim of this study was to evaluate the protective effect of heat-killed Enterococcus faecalis EF-2001 (EF-2001) on a model of inflammatory bowel disease (IBD). A total of 28 female NC/Nga mice were divided into 4 treatment groups. Controls were fed a normal commercial diet. In the experimental groups, colitis was induced by rectal administration of dinitrobenzene sulfonic acid. Two groups were orally administered 2 and 17 mg/kg EF-2001, respectively. EF-2001 treatment decreased the expression of several cytokines, including cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), interferon (IFN)-γ, interleukin (IL)-1β, and IL-6 in inflamed colon compared to the DNBS alone group. In addition, EF-2001 suppressed DNBS-induced colonic tissue destruction. Therefore, this study strongly suggests that EF-2001 could alleviate the inflammation associated with mouse IBD.

Effect of Enterococcus faecalis 2001 on colitis and depressive-like behavior in dextran sulfate sodium-treated mice: involvement of the brain–gut axis

“…This effect was similar to that of steroids, which are commonly prescribed for treating IBD [52]. Recently, other researchers have reported that EF-2001 protects dinitrobenzene sulfonic acid-induced colitis, a chemically induced colitis model, via a decrease in inflammatory cytokines [30]. Thus, the anti-inflammatory effect of EF-2001 may also be related to reduced inflammatory cytokines.…”

“…NFκB p65 activation inhibits apoptosis by increasing X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptotic factor that exerts its action by regulating caspase-3 activity [26, 27]. EF-2001 can decrease serum inflammatory cytokines in a contact dermatitis model mouse [28], has anti-tumor effects [29], and protects chemical-induced colitis [30]. Therefore, we hypothesized that EF-2001 may attenuate inflammation and apoptosis in DSS-treated mice.…”

Researching New Therapeutic Approaches for Abdominal Visceral Pain Treatment: Preclinical Effects of an Assembled System of Molecules of Vegetal Origin

“…During this phase, the appearance of a series of IBS-like symptoms is observed: visceral hypersensitivity, motility disorder and alterations of the permeability or the secretion that also persist in the animals during the phase of recovery from the colitis [30]. Moreover, DNBS also causes IBD-like symptoms such as intestinal mucosal and transmural damage, intestinal motility dysfunction, release of pro-inflammatory cytokines, and dysbiosis [31].…”

Recent update on lactic acid bacteria producing riboflavin and folates: application for food fortification and treatment of intestinal inflammation

“…LAB have shown that can counteract inflammatory processes in the GIT through different mechanisms, this was demonstrated using animal models of IBD and intestinal mucositis (IM), and in clinical trials, being the intestinal microbiota and host's immune response modulation the most evaluated (dos Ferreira dos Santos et al 2016;Tang et al 2017;Yokota et al 2018;Choi et al 2019).…”